Log in to save to my catalogue

Acquired Resistance to KRAS G12C Inhibition in Cancer

Acquired Resistance to KRAS G12C Inhibition in Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34161704

Publication information

Publisher

United States

More information

Scope and Contents

Contents

Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS
). The mechanisms of acquired resistance to these therapies are currently unknown.
Among patients with
-mutant cancers treated with adagrasib monotherapy, we p...

Alternative Titles

Full title

Acquired Resistance to KRAS G12C Inhibition in Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmed_primary_34161704

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34161704

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2105281

How to access this item